期刊文献+

临床药师参与1例侵袭性肺曲霉病个体化治疗分析 被引量:3

Participation of the Clinical Pharmacist in the Individual Treatment of a Patient with Invasive Pulmonary Aspergillosis
下载PDF
导出
摘要 目的探讨临床药师对侵袭性肺曲霉病的药学服务方法。方法以1例侵袭性肺曲霉病患者的诊治过程为基础,从伏立康唑的血药浓度监测、CYP2C19代谢酶的基因多态性、药品不良反应等方面讨论临床药师对侵袭性肺曲霉病患者的药学服务。结果临床药师参与评估患者状况,积极给予药学服务,取得较好疗效。结论临床药师应发挥个体化精准用药干预作用,协助医师制订合理的抗真菌治疗方案,促进抗真菌药物的合理应用。 Objective To investigate the way to develop pharmaceutical care for a patient with invasive pulmonary aspergillosis.Methods Based on the diagnosis and treatment of a patient with invasive pulmonary aspergillosis,the pharmaceutical care of the clinical pharmacist for a patient with invasive pulmonary aspergillosis was investigated from the aspects of the blood concentration monitoring of voriconazole,gene polymorphism of CYP2 C19 metabolizing enzyme and adverse drug reactions.Results The clinical pharmacist participated in the evaluation of the patient’s condition and actively gave pharmaceutical care,which had good efficacy.Conclusion The clinical pharmacist can play an individualized and precise role in the drug intervention and assist physicians to formulate rational antifungal regimen,which can promote clinical rational application of antifungal drugs.
作者 徐文俊 陆康生 朱华 孙家艳 李贤文 XU Wenjun;LU Kangsheng;ZHU Hua;SUN Jiayan;LI Xianwen(Northern Jiangsu People′s Hospital,Clinical Medical School of Yangzhou University,Yangzhou,Jiangsu,China 225001)
出处 《中国药业》 CAS 2019年第23期85-87,共3页 China Pharmaceuticals
基金 江苏省2016年度院级科研课题[yzucms201632]
关键词 侵袭性肺曲霉病 血药浓度监测 遗传多态性 临床药师 药学服务 invasive pulmonary aspergillosis blood concentration monitoring genetic polymorphism clinical pharmacist pharmaceutical care
  • 相关文献

参考文献5

二级参考文献49

  • 1曹永兵,张磊,王彦,姜远英.伏立康唑及其临床应用[J].中国新药与临床杂志,2005,24(4):330-332. 被引量:48
  • 2PFALLER MA,ZHANG J,MESSER SA,et al. In vitro activities of voriconazole, ftubonazol,and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother, 1999,43 ( 1 ) : 169 - 171.
  • 3SUTTON DA, SANCHE SE, REVANKAR SG, et al. In vitro amplhoteriein B resistance in clinical isolates of Aspergillus terreus,with a head-to-head comparison to voriconazole. J ClinMicro2biol, 1999,37 (7) :2343.
  • 4DENNING DW,R IBAUD P,MILP IED N,et al. Efficacy and safety of vorieonazole in the treatment of acute invasive aspergillosis. Clin Infect Dis,2002,34(5) :563-571.
  • 5Becker M J, Lugtenburg E J, Cornelissen J J, et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol, 2003; 121:448 ~ 457
  • 6Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphoteric in B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis, 2000;31:1155~ 1163
  • 7Takemoto K, Yamamoto Y, Ueda Y, et al. Comparative studies on the efficacy of AmBisome and fungizone in a mouse model of disseminated aspergillosis. J Antimicrob Chemother,2004;53:311 ~ 317
  • 8Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol, 2003; 109: 111 ~ 118
  • 9Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med ,2002;347:408 ~ 415
  • 10Yuet W. Voriconazole versue amphotericin for primary therapy of invasive aspergillosis. N Engl J Med, 2002; 347: 408 ~ 415

共引文献142

同被引文献28

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部